US leadership is key – US CP
U.S. Mission China, 5-13-2022, https://china.usembassy-china.org.cn/u-s-fact-sheet-the-2nd-global-covid-summit/, "U.S. FACT SHEET: The 2nd Global COVID-19 Summit:," U.S. Embassy & Consulates in China (ermo/sms, Acc:6-20-2022)
Expanded investments in bilateral global health security programs. To advance the Global Health Security Agenda and to accelerate the implementation of U.S. Global Health Security Strategy, the U.S. government will expand the number of global health security intensive support partner countries by eight this year, including to three new regions. This will improve countries’ capacities to prevent, detect, and respond to future COVID-19 variants and future health threats.
Expanding dose donation types to include boosters and pediatric doses to accelerate global vaccine coverage. The United States is expanding Pfizer vaccine dose types being donated globally to now include boosters and pediatric doses, as part of our 1 billion Pfizer dose donation commitment. This will help accelerate progress towards the 70% vaccination target and expand the availability of doses available for those at highest risk and for children globally.
Improving guidance for vaccine development to enhance protection. The United States, through the FDA, is committing to help align global health authorities and the WHO to provide advice to COVID-19 vaccine producers to inform which strains they use as the basis for vaccines, using predictions about the predominance of future strains and which strains will lead to vaccines that provide the broadest protection against unknown future variants.
Financing facility for COVID-19 vaccine and ancillary supply purchases and delivery through the U.S. International Development Finance Corporation (DFC). DFC has set up a vehicle to provide up to $1 billion to Gavi, the Vaccine Alliance, to provide bridge financing guaranteeing commitments from other donors. This will allow COVAX to react immediately in a crisis to purchase and deliver ancillary supplies and vaccines on behalf of developing countries participating in the COVAX Advance Market Commitment.
Advancing COVID-19 vaccine research and development through the Coalition for Epidemic Preparedness Innovations (CEPI). At least $50 million of the U.S. Government’s recent $150 million, 3-year pledge to CEPI will support COVID-19 vaccine research in addition to the development of other vaccines and countermeasures for future emerging infectious diseases, with the goals of making vaccines more broadly protective and easier to administer in low-resource settings.
Despite these commitments to combat COVID-19 and enhance future preparedness against health threats, there is more work to be done to ensure the United States can continue to lead, to make Americans and the world safer. President Biden continues to urge Congress to act promptly to provide supplemental resources. Without additional emergency funding, the United States will be unable to purchase additional life-saving treatments for the American people. The United States will be less able to stop the spread of possible new variants from around the world. The United States will be unable to keep vaccinating the world against COVID-19 and getting shots into arms, to save lives here at home and abroad.